Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2024.2436433 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Alejandro Valdés und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Bradford Hill Clinical Research Center, Santiago, Chile. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Proteins, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 103 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Belzutifan is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets the von Hippel-Lindau protein (pVHL)-HIF-vascular endothelial growth factor (VEGF) pathway, which is crucial in cellular responses to hypoxia. By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis. AREAS COVERED: In this review, we describe the pVHL-HIF-VEGF pathway and how it led to the development of HIF inhibitors, including belzutifan. A search was conducted for trials involving Belzutifan, including phase I-III trials. We describe the relevant toxicity, with emphasis on hypoxia and anemia. EXPERT OPINION: Belzutifan is a relatively safe drug, with manageable adverse events, including anemia and hypoxia as on-target toxicity. Ongoing trials are studying its benefit in overall survival for RCC in first-line treatment and its potential in other malignancies. The LITESPARK-005 trial reported the benefit of belzutifan in progression-free survival (PFS) compared to everolimus in later lines of treatment, with improvement in quality-of-life outcomes. Given its different mechanism of action to currently available treatments, belzutifan is expected to play a prominent role in the treatment of clear cell renal carcinoma and other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Bradford Hill Clinical Research Center, Santiago, Chile.
- Department of Medical Oncology, Instituto Nacional del Cáncer, Santiago, Chile.
- Department of Medical Oncology, Hospital Sótero del Río, Santiago, Chile.
ORCID-Profile: Alejandro Valdés, Gonzalo Pizarro, Jaime González-Montero, Mauricio Burotto
Zitieren
APA
Valdés, A., Pizarro, G., González-Montero, J., Rojas, C., & Burotto, M. (2025). Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2436433
Vancouver
Valdés A, Pizarro G, González-Montero J, Rojas C, Burotto M. Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2024.2436433
BibTeX
@article{Valds2025,
author = {Valdés, Alejandro and Pizarro, Gonzalo and González-Montero, Jaime and Rojas, Carlos and Burotto, Mauricio},
title = {Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2024.2436433}
}
EUVIMED